Novo Nordisk’s CFO said the company’s semaglutide patent in India will expire in the coming months, likely increasing generic competition in the obesity drug market. The executive also noted that while “most-favored nation” pricing impacts U.S. prices, a growing cash-pay segment is the larger driver.
Show moreStay Ahead – Explore Now! India’s CV Market to Cross Pre-Pandemic Peak by FY26
Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.
Powered By Just Imagine
